When the Referee Owns the Team — and Tennessee Changes the Rules
At the center of this issue is a simple question: should the entities responsible for managing prescription drug benefits also own the pharmacies that profit from those decisions?
At the center of this issue is a simple question: should the entities responsible for managing prescription drug benefits also own the pharmacies that profit from those decisions?
Delayed remediation and patch latency are no longer just IT and security metrics; they serve as direct reflections of leadership priorities.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Difficult packaging comes with tangible consequences, including lower adherence, higher rates of adverse events, and diminished real-world effectiveness. It can also delay FDA submissions and ultimately, market entry.
Payment friction isn't always obvious. It shows up in extended accounts receivable timelines, increased billing inquiries, and patients who delay payment – not because they're unwilling to pay, but because the process made it harder than it needed to be.
The phenomenon of taking five or more medicines at the same time has become so common that it now has its own term – polypharmacy – and there is no doubt that it increases the risk of dizziness, confusion, and loss of balance.
Now is the time to solve the industry’s identity crisis, and it can only be done through a combination of phishing-resistant and adaptive MFA, fine-grained access control, and standards-based interoperability.
As radiopharmaceuticals continue to evolve, the convergence of scientific innovation, operational practicality, and clinical expertise is opening new possibilities in oncology.
Direct-to-patient (DTP) models create a continuous loop of value, connecting seamless patient and provider experience with the strategic power of branding and data.
Consumers are inundated with false information circulating online about GLP-1 medicines, which causes confusion and can lead to potentially serious health problems resulting from dosing errors and adverse reactions to ingredients in compounded GLP-1 products.
Today’s technology has the potential to empower independent pharmacies to offer adherence support at a greater scale — and healthcare engagements that overlook this touchpoint miss out.
Over the past 15 years, financial and administrative barriers – most notably step therapy mandates and prior authorization requirements – have repeatedly forced patients through suboptimal or ineffective treatments before they can try another therapy, have tied the hands of healthcare professionals and patients alike. Now there's a possible solution.
Utah is piloting an AI system developed by Doctronic to autonomously handle routine prescription refills, aiming to reduce delays and boost medication adherence. But a report from Mindgard AI claiming that there are vulnerabilities in the company’s chatbot underscores the broader challenge regulators and developers face in ensuring healthcare AI systems remain safe and reliable in real-world use.
Congress has already granted the FDA flexibility in evaluating therapies for rare diseases, including the use of real-world evidence and natural history data when traditional large-scale trials are not feasible. The question before the FDA now is not if those tools can be applied – they can – but if the agency has the courage to use them before more patients lose their autonomy, and ultimately, their lives, to rare disease.
In the latest episode of the Debunked Podcast, the discussion revolved around the Break Up Big Medicine legislation to rein in healthcare giants and ways to introduce meaningful PBM reform.